Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats

Clinical and Experimental Medicine

Volumn 9, Issue 1, 2009, Pages 73-76

  Yamagishi, S ^a   Matsui, T ^a   Nakamura, K ^a   Takenaka, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

PAI 1; PEDF; Platelet aggregation; Thrombogenic tendency

Indexed keywords

EYE PROTEIN; FIBRINOLYTIC AGENT; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ANIMAL; ARTICLE; DRUG EFFECT; RAT; SPRAGUE DAWLEY RAT; THROMBOCYTE AGGREGATION;

ANIMALS; EYE PROTEINS; FIBRINOLYTIC AGENTS; NERVE GROWTH FACTORS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; SERPINS;

EID: 66449131767     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-008-0010-4     Document Type: Article

References (11)

1. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T (2006) Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 3:73-77
2. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Jinnouchi Y, Yoshida Y, Ueda S, Katsuki Y, Katsuda Y, Imaizumi T (2008) Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis 197:25-33 (Pubitemid 351273269)
3. Tombran-Tink J, Barnstable CJ (2003) PEDF: a multifaceted neurotropic factor. Nat Rev Neurosci 4:628-636
4. Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, Imaizumi T (2004) Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 37:497-506 (Pubitemid 38953377)
5. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T (2006) Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 281:20213-20220 (Pubitemid 44065796)
6. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y, Yoshida Y, Ueda S, Adachi H, Imaizumi T (2007) Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 170:2159-2170 (Pubitemid 47339287)
7. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z (2002) Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end productinduced injury through its antioxidative properties. Biochem Biophys Res Commun 296:877-882
8. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, Loscalzo J (1994) Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 84:1416-1421 (Pubitemid 29293220)
9. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, Hino A, Jinnouchi Y, Takenaka K, Matsui T, Nakamura K, Imaizumi T (2006) Elevated serum levels of pigment epitheliumderived factor in the metabolic syndrome. J Clin Endocrinol Metab 91:2447-2450 (Pubitemid 43855041)
10. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T, Nakamura K, Imaizumi T (2007) Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 39:845-858
11. Vaughan DE (2005) PAI-1 and atherothrombosis. J Thromb Haemost 3:1879-1883 (Pubitemid 41716575)